Published in Cochrane Database Syst Rev on August 22, 2016
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag | NCT01147809
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia | NCT02052882
A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia | NCT02094417
A Rollover Study to Provide Continued Treatment With Eltrombopag | NCT01957176
Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag | NCT00688272
Eltrombopag for Moderate Aplastic Anemia | NCT01328587
Eltrombopag for Post Transplant Thrombocytopenia | NCT01000051
Safety of Romiplostim (Nplate®) Following UCBT | NCT02046291
A Study of Eltrombopag in Patients With CMML and Thrombocytopenia | NCT02323178
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) | NCT01168921
Study of Eltrombopag in Platelet Refractory Thrombocytopenia | NCT01194167
Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia. (ITP0511) | NCT01791101
A Safety and Efficacy Study of Eltrombopag in Subjects With AML | NCT01890746
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med (1998) 19.07
Practical methods for incorporating summary time-to-event data into meta-analysis. Trials (2007) 14.51
Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet (2012) 5.44
Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med (2010) 5.23
Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med (1997) 4.44
Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol (2009) 4.44
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol (2010) 4.12
Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. Br J Cancer (2004) 4.06
Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med (2012) 3.93
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood (2006) 3.85
Hematopoietic stem cell transplantation: a global perspective. JAMA (2010) 3.63
Guidelines for the use of platelet transfusions. Br J Haematol (2003) 3.45
Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion (1985) 3.35
Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood (2002) 3.18
A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med (2013) 2.90
Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion (2003) 2.48
Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost (2005) 2.46
Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 2.33
Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood (2001) 2.21
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood (2008) 2.04
The EBMT activity survey: 1990-2010. Bone Marrow Transplant (2012) 1.96
Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood (2005) 1.94
Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology (2009) 1.63
Transfusion guidelines for neonates and older children. Br J Haematol (2004) 1.61
A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leuk Lymphoma (2012) 1.57
Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood (1997) 1.57
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol (2015) 1.43
Lack of efficacy of tranexamic acid in thrombocytopenic bleeding. Transfusion (1991) 1.40
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol (2009) 1.39
Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood (2009) 1.37
Evidence-based platelet transfusion guidelines. Hematology Am Soc Hematol Educ Program (2007) 1.34
Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth (2010) 1.30
The platelet as an immune cell-CD40 ligand and transfusion immunomodulation. Immunol Res (2009) 1.25
A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood (2008) 1.25
Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill. Br J Haematol (2009) 1.23
Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev (2012) 1.15
ABO-identical versus nonidentical platelet transfusion: a systematic review. Transfusion (2009) 1.13
DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood (1984) 1.10
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood (2010) 1.09
Pharmacokinetics and safety of fibrinogen concentrate. J Thromb Haemost (2009) 1.06
Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev (2004) 1.05
Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica (2009) 1.04
The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion (1974) 1.04
Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev (2012) 1.03
Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev (2013) 1.02
Screening of platelets for bacterial contamination at the Welsh Blood Service. Transfus Med (2010) 1.01
Biology and chemistry of thrombopoietic agents. Semin Hematol (2010) 1.00
Platelet transfusions in haematology patients: are we using them appropriately? Vox Sang (2012) 1.00
TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database Syst Rev (2011) 1.00
Platelet mimetic particles for targeting thrombi in flowing blood. Adv Mater (2012) 0.98
Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer (2010) 0.97
Platelet utilization in the developing world: strategies to optimize platelet transfusion practices. Transfus Apher Sci (2009) 0.96
DDAVP: does the drug have a direct effect on the vessel wall? Thromb Res (1983) 0.94
Platelet utilization and the transfusion trigger: a prospective analysis. Transfusion (2007) 0.94
Measurement of bleeding severity: a critical review. Transfusion (2004) 0.93
The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion (2013) 0.91
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol (2012) 0.91
Substitutes and alternatives to platelet transfusions in thrombocytopenic patients. J Thromb Haemost (2003) 0.90
Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet (1996) 0.90
Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion (2008) 0.90
A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Curr Med Res Opin (2010) 0.90
The role of fibrinogen: a new paradigm in the treatment of coagulopathic bleeding. Thromb Res (2011) 0.90
Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther (2009) 0.89
Recombinant human thrombopoietin improves platelet counts and reduces platelet transfusion possibility among patients with severe sepsis and thrombocytopenia: a prospective study. J Crit Care (2013) 0.89
Evaluation of platelet transfusion triggers in a tertiary-care hospital. Transfusion (2007) 0.88
Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. Cochrane Database Syst Rev (2013) 0.88
Methods for the analysis of bleeding outcomes in randomized trials of PLT transfusion triggers. Transfusion (2004) 0.87
Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet (1989) 0.87
Novel platelet products, substitutes and alternatives. Transfus Clin Biol (2001) 0.86
The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. Bone Marrow Transplant (2007) 0.86
Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood (2015) 0.86
Off-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials. Vox Sang (2008) 0.86
The impact of thrombopoietin on clinical practice. Curr Pharm Des (2002) 0.86
Does arginine vasopressin influence the coagulation system in advanced vasodilatory shock with severe multiorgan dysfunction syndrome? Anesth Analg (2004) 0.85
Emerging treatments for thrombocytopenia: increasing platelet production. Drug Discov Today (2008) 0.85
Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials. Br J Haematol (2014) 0.85
Novel platelet substitutes: disk-shaped biodegradable nanosheets and their enhanced effects on platelet aggregation. Bioconjug Chem (2009) 0.85
Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer (2014) 0.85
Effect of hepatic or renal impairment on eltrombopag pharmacokinetics. J Clin Pharmacol (2010) 0.84
Plasma transfusion for bedside, radiologically guided, and operating room invasive procedures. Transfusion (2012) 0.84
Recombinant activated factor VII as a general haemostatic agent: evidence-based efficacy and safety. Curr Drug Saf (2007) 0.83
Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion (2013) 0.83
Does bleeding affect patient-reported outcome measures in patients with myelodysplasia or hematologic malignancies: a systematic review. Transfusion (2013) 0.83
[Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]. Dtsch Med Wochenschr (1982) 0.83
The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer (1993) 0.83
Menatetrenone, a vitamin K2 analog, ameliorates cytopenia in patients with refractory anemia of myelodysplastic syndrome. Ann Hematol (2001) 0.83
Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol (2000) 0.82
Thrombopoietin-receptor agonists. Curr Opin Hematol (2012) 0.82
Effect of beta-blockers, Ca2+ antagonists, and benzodiazepines on bleeding incidence in patients with chemotherapy induced thrombocytopenia. Platelets (2010) 0.82
Recombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2014) 0.82
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Oncol (2007) 0.81
Prophylactic fresh frozen plasma may prevent development of hepatic VOD after stem cell transplantation via ADAMTS13-mediated restoration of von Willebrand factor plasma levels. Bone Marrow Transplant (2007) 0.81
Development of fibrinogen gamma-chain peptide-coated, adenosine diphosphate-encapsulated liposomes as a synthetic platelet substitute. J Thromb Haemost (2008) 0.81
A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. Eur J Haematol (2014) 0.81
A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2000) 0.81
CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ (2010) 28.70
CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol (2010) 7.04
Publishing protocols of systematic reviews: comparing what was done to what was planned. JAMA (2002) 5.87
CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg (2011) 3.57
Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J (2008) 2.99
Clinical trials should begin and end with systematic reviews of relevant evidence: 12 years and waiting. Lancet (2010) 2.96
A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med (2013) 2.90
Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev (2012) 2.78
Age of transfused blood in critically ill adults. N Engl J Med (2015) 2.52
Evidence-based selection of theories for designing behaviour change interventions: using methods based on theoretical construct domains to understand clinicians' blood transfusion behaviour. Br J Health Psychol (2009) 2.50
Systematic reviews of diagnostic tests in cancer: review of methods and reporting. BMJ (2006) 2.12
Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report. J R Soc Med (2007) 1.95
Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy donors. Cochrane Database Syst Rev (2009) 1.74
End-to-end electronic control of the hospital transfusion process to increase the safety of blood transfusion: strengths and weaknesses. Transfusion (2006) 1.71
An international survey indicated that unpublished systematic reviews exist. J Clin Epidemiol (2009) 1.70
Prevalence, management, and outcomes of critically ill patients with prothrombin time prolongation in United Kingdom intensive care units. Crit Care Med (2010) 1.66
Ear drops for the removal of ear wax. Cochrane Database Syst Rev (2009) 1.60
A cross-country comparison of intensive care physicians' beliefs about their transfusion behaviour: a qualitative study using the Theoretical Domains Framework. Implement Sci (2012) 1.51
Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics (2004) 1.49
Brief review: Supplementing oxygen through an airway exchange catheter: efficacy, complications, and recommendations. Can J Anaesth (2011) 1.48
Factors affecting red blood cell storage age at the time of transfusion. Transfusion (2013) 1.47
Is fresh-frozen plasma clinically effective? An update of a systematic review of randomized controlled trials. Transfusion (2012) 1.46
A multicomponent decision tool for prioritising the updating of systematic reviews. BMJ (2013) 1.42
The difficult airway with recommendations for management--part 2--the anticipated difficult airway. Can J Anaesth (2013) 1.42
Immunoplatelet counting: potential for reducing the use of platelet transfusions through more accurate platelet counting. Br J Haematol (2003) 1.39
PRISMA for Abstracts: reporting systematic reviews in journal and conference abstracts. PLoS Med (2013) 1.36
The acute management of trauma hemorrhage: a systematic review of randomized controlled trials. Crit Care (2011) 1.34
Clinical controversies: etomidate as an induction agent for endotracheal intubation in patients with sepsis: continue to use etomidate for intubation of patients with septic shock. Ann Emerg Med (2008) 1.30
Using theories of behaviour to understand transfusion prescribing in three clinical contexts in two countries: development work for an implementation trial. Implement Sci (2009) 1.29
Concepts of blood transfusion in adults. Lancet (2013) 1.28
Assessment of the quality of reporting in abstracts of randomized controlled trials published in five leading Chinese medical journals. PLoS One (2010) 1.27
Reviews assessing the quality or the reporting of randomized controlled trials are increasing over time but raised questions about how quality is assessed. J Clin Epidemiol (2010) 1.21
Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev (2012) 1.15
Protocol for CONSORT-SPI: an extension for social and psychological interventions. Implement Sci (2013) 1.13
Empty reviews: a description and consideration of Cochrane systematic reviews with no included studies. PLoS One (2012) 1.11
The difficult airway with recommendations for management--part 1--difficult tracheal intubation encountered in an unconscious/induced patient. Can J Anaesth (2013) 1.08
Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer--a systematic review and meta-analysis. Hum Reprod Update (2012) 1.07
Surgical versus conservative interventions for treating anterior cruciate ligament injuries. Cochrane Database Syst Rev (2016) 1.07
Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev (2009) 1.06
The desperate need for good-quality clinical trials to evaluate the optimal source and dose of fibrinogen in managing bleeding. Crit Care (2011) 1.06
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev (2014) 1.06
Red cell transfusion for the management of upper gastrointestinal haemorrhage. Cochrane Database Syst Rev (2010) 1.05
Reporting on covariate adjustment in randomised controlled trials before and after revision of the 2001 CONSORT statement: a literature review. Trials (2010) 1.05
European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol (2003) 1.05
Long-term effects of autologous bone marrow stem cell treatment in acute myocardial infarction: factors that may influence outcomes. PLoS One (2012) 1.05
New strategies for the optimal use of platelet transfusions. Hematology Am Soc Hematol Educ Program (2008) 1.04
Reporting of effect direction and size in abstracts of systematic reviews. JAMA (2011) 1.03
Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev (2012) 1.03
Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev (2013) 1.02
A systematic review of the effect of red blood cell transfusion on mortality: evidence from large-scale observational studies published between 2006 and 2010. BMJ Open (2013) 1.00
Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors. Cochrane Database Syst Rev (2014) 0.99
What is the maximum time that a unit of red blood cells can be safely left out of controlled temperature storage? Transfus Med Rev (2011) 0.99
Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis. CMAJ (2010) 0.98
Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev (2009) 0.97
Developing a reporting guideline for social and psychological intervention trials. Trials (2013) 0.96
Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev (2016) 0.96
Restrictive vs liberal blood transfusion for acute upper gastrointestinal bleeding: rationale and protocol for a cluster randomized feasibility trial. Transfus Med Rev (2013) 0.95
Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review. Am J Hematol (2009) 0.94
Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev (2011) 0.94
Update on the transfusion in gastrointestinal bleeding (TRIGGER) trial: statistical analysis plan for a cluster-randomised feasibility trial. Trials (2013) 0.93
Antidepressants for patients with tinnitus. Cochrane Database Syst Rev (2012) 0.93
Corticosteroids as adjuvant to antiviral treatment in Ramsay Hunt syndrome (herpes zoster oticus with facial palsy) in adults. Cochrane Database Syst Rev (2008) 0.92
Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev (2015) 0.91
Poor adherence of randomised trials in surgery to CONSORT guidelines for non-pharmacological treatments (NPT): a cross-sectional study. BMJ Open (2013) 0.91
The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion (2013) 0.91
The safety and efficacy of red cell transfusions in neonates: a systematic review of randomized controlled trials. Br J Haematol (2012) 0.90
Resources for authors of reports of randomized trials: harnessing the wisdom of authors, editors, and readers. Trials (2011) 0.90
Challenges and opportunities to prevent transfusion errors: a Qualitative Evaluation for Safer Transfusion (QUEST). Transfusion (2012) 0.90
Application of theory to enhance audit and feedback interventions to increase the uptake of evidence-based transfusion practice: an intervention development protocol. Implement Sci (2014) 0.89
Red blood cell transfusion for people undergoing hip fracture surgery. Cochrane Database Syst Rev (2015) 0.89
Prevalence, management, and outcomes of patients with coagulopathy after acute nonvariceal upper gastrointestinal bleeding in the United Kingdom. Transfusion (2012) 0.89
The clinical effects of red blood cell transfusions: an overview of the randomized controlled trials evidence base. Transfus Med Rev (2011) 0.89
Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. Cochrane Database Syst Rev (2013) 0.88
Methods for obtaining unpublished data. Cochrane Database Syst Rev (2011) 0.87
The incidence and outcomes of fetomaternal alloimmune thrombocytopenia: a UK national study using three data sources. Br J Haematol (2011) 0.87
Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev (2015) 0.87
Red blood cell transfusion practice in patients presenting with acute upper gastrointestinal bleeding: a survey of 815 UK clinicians. Transfusion (2011) 0.86